Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Parasite protein thiols refer to the sulfhydryl (-SH) groups found on various essential proteins within parasitic organisms, including protozoa and helminths [1, 3]. These thiols are critical components of the parasite's antioxidant defense and redox signaling systems, which protect the pathogen from oxidative damage inflicted by the host's immune response [1, 9]. Key enzymes in this category include trypanothione reductase, thioredoxin reductase, and various cysteine proteases [2, 4, 10]. Drugs targeting these thiols, such as gold-containing auranofin or arsenical compounds like melarsoprol, typically act by forming covalent bonds with the sulfur atom, thereby inactivating the protein and disrupting the parasite's metabolic and protective pathways [5, 6]. Because many of these thiol-dependent systems are unique to parasites or significantly different from their human counterparts, they represent attractive targets for the development of selective antiparasitic therapies [4, 9].
Covalent modification or oxidation of sulfhydryl groups on essential parasite proteins, leading to enzyme inactivation and lethal oxidative stress [1, 5, 6].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parasite protein thiols.